ZEPLIFY

EUIPO EUIPO 2021 Application withdrawn

Protect this trademark from copycats!

With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.

The Union trademark ZEPLIFY was filed as Word mark on 02/04/2021 at the European Union Intellectual Property Office. The current status of the mark is "Application withdrawn".

Trademark Details Last update: February 8, 2024

Trademark form Word mark
File reference 018390102
Application date February 4, 2021
Publication date April 26, 2021

Trademark owner

Lilly Corporate Center
46285 Indianapolis
US

Trademark representatives

Widenmayerstr. 10 80538 München DE

Objection / Complaint

05/27/2021: Likelihood of confusion
Trademark
Applicant
CROSSJECT

goods and services

5 Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment, prevention and diagnosis of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders; Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment, diagnosis and prevention of fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders; Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment, diagnosis and prevention of migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases; Diagnostic agents, preparations and substances for medical purposes; diagnostic scanning agents for medical use, namely, diagnostic scanning agents for in vivo use; radiopharmaceutical diagnostic preparations for medical use; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative amyloid diseases; pharmaceutical preparations

ID: 11018390102